Trial · NCT00504023
Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
NCT00504023, Not applicable, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2018-05-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva. Trials, record NCT00504023. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00504023
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
- NCT number
- NCT00504023
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 8 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Vulvar Cancer
- Interventions
- imiquimod, biopsy, therapeutic conventional surgery
- First posted
- 2007-07-19
- Last updated
- 2018-06-06
- Results first posted
- 2018-05-08
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Clinical and Histologic Remission | 12 weeks post treatment | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Clinical and Histologic Remission | 12 weeks post treatment | % of participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Clinical and Histologic Remission | Imiquimod | 75 | % of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Imiquimod | 8 | |
| Overall Study | COMPLETED | Imiquimod | 8 | |
| Overall Study | NOT COMPLETED | Imiquimod | 0 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dry Eye | Eye disorders | Imiquimod | 1 | 8 | |
| other | Dry mouth | Gastrointestinal disorders | Imiquimod | 1 | 8 | |
| other | Fatigue | General disorders | Imiquimod | 1 | 8 | |
| other | Pain - Head/Headache | Nervous system disorders | Imiquimod | 1 | 8 | |
| other | Pain - Joint | Musculoskeletal and connective tissue disorders | Imiquimod | 1 | 8 | |
| other | Pain - Muscle | Musculoskeletal and connective tissue disorders | Imiquimod | 1 | 8 | |
| other | Pruritus/Itching | Skin and subcutaneous tissue disorders | Imiquimod | 1 | 8 | |
| other | Rash/desquamation | Skin and subcutaneous tissue disorders | Imiquimod | 1 | 8 | |
| serious | Pain - Joint | Musculoskeletal and connective tissue disorders | Imiquimod | 1 | 8 | |
| serious | Pain - Muscle | Musculoskeletal and connective tissue disorders | Imiquimod | 1 | 8 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Imiquimod | 0 | 8 |
| Total, other adverse events | Imiquimod | 8 | 8 |
| Total, serious adverse events | Imiquimod | 1 | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00504023
GET https://conductscience.org/api/trials/v1/NCT00504023/registered